Search

Your search keyword '"Galyavich AS"' showing total 529 results

Search Constraints

Start Over You searched for: Author "Galyavich AS" Remove constraint Author: "Galyavich AS"
529 results on '"Galyavich AS"'

Search Results

1. Current approaches to the treatment of hypertensive patients in view of modern guidelines

2. Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023)

3. Analysis of data from the Russian AURA registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease)

4. Results of the Russian Society of Cardiology survey 'Chronic heart failure. Unsolved issues'

5. Real Clinical Practice Register of Albuminuria Detection in Patients with Previously Undiagnosed Chronic Kidney Disease

6. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

7. Peculiarities of polyvascular disease and the diagnostic significance of the ankle-brachial index in patients with coronary artery disease: results from the real-world registry KAMMA (Clinical registry on patient population with polyvascular disease in the Russian Federation and Eurasian countries)

8. Combination of Takotsubo cardiomyopathy with cardiac myxoma: a case report

9. Hypertension in periand postmenopausal women: mechanisms, management, observation

10. Clinical characteristics of carriers of pathogenic LDLR and АРОВ mutations

11. Prognostic value of diagnostic criteria for familial hypercholesterolemia in men and women with dyslipidemia

12. Interim analysis of a prospective observational multicenter registry study of patients with chronic heart failure in the Russian Federation 'PRIORITET-CHF': initial characteristics and treatment of the first included patients

13. About the classification of heart failure

14. Growth differentiation factor-15 — a new indicator of unfavorable prognosis in uncomplicated myocardial infarction

15. Relationships and Activities. The study is supported by OOO AstraZeneca Phar­maceuticals.

16. Disorders of lipid metabolism. Clinical Guidelines 2023

17. Newly diagnosed diseases and the frequency of their occurrence in patients after a new coronavirus infection. Results of an International Register 'Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)' (12-month follow-up)

18. Practical aspects of vericiguat therapy in patients with heart failure with reduced ejection fraction. Expert council resolution

19. Possibilities of lipid clinics in identifying patients with familial hypercholesterolemia

20. Practical guidelines for the diagnosis and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM or transthyretin cardiac amyloidosis)

21. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

22. Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis

23. ACTIV SARS-CoV-2 registry (Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients). Assessment of impact of combined original comorbid diseases in patients with COVID-19 on the prognosis

24. Clinical features of post-COVID period. Results of an International Register 'Dynamics Analysis of Comorbidities in SARS-CoV-2 Survivors (ACTIV SARS-CoV-2)' (12-month follow-up)

25. Empagliflozin and heart failure: position paper of the experts on the results of the online meeting and discussion of the EMPEROR-Preserved Trial

27. Eurasian guidelines for the diagnosis and treatment of pulmonary hypertension (2023)

28. Lipid profile in hospitalized patients with COVID-19 depending on the outcome of its acute phase: data from the international registry 'Dynamics analysis of comorbidities in SARS-CoV-2 infection survivors'

29. Skin manifestations of secondary dyslipidemia: a case report

30. Influence on the autonomic cardiovascular system regulation in the treatment of hypertension, arrhythmias and heart failure

31. Effective drug modification of risk factors in a patient with coronary artery disease: a case report

32. Riociguat treatment in patients with chronic thromboembolic pulmonary hypertension: Final safety data from the EXPERT registry

33. Riociguat treatment in patients with pulmonary arterial hypertension: Final safety data from the EXPERT registry

34. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (2020)

35. Expert consensus. Effect of antihypertensive therapy on cognitive functions

36. Aspects of efficacy, safety and adherence to antihypertensive therapy with single pill combinations of valsartan, amlodipine and hydrochlorothiazide (Vamloset® and Co-Vamloset) in patients with 2 and 3 grade of arterial hypertension in the Russian clinical study VICTORY II

37. Empagliflozin in patients hospitalized for acute decompensated heart failure: an expert resolution on the discussion of the EMPULSE trial

38. Pharmacoepidemiological analysis of routine management of heart failure patients in the Russian Federation. Part II

40. EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020)

41. EURASIAN CLINICAL GUIDELINES ON DIAGNOSIS AND TREATMENT OF PULMONARY HYPERTENSION

42. Approaches to the therapy of heart failure with reduced ejection fraction. Resolution of an online meeting of the Volga Federal District experts

43. 2020 Clinical practice guidelines for Pulmonary hypertension, including chronic thromboembolic pulmonary hypertension

44. Clinical features of post-COVID-19 period. Results of the international register 'Dynamic analysis of comorbidities in SARS-CoV-2 survivors (AKTIV SARS-CoV-2)'. Data from 6-month follow-up

45. Principles of organization of medical care for patients with heart failure in the system of cardiovascular risk management: focus on continuity of care and patient routing. Practical materials

46. Practical efficacy and safety of Konsilar D24 in patients with hypertension: data from the KONSONANS program

47. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial

48. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter

49. Resolution of an online meeting of the Volga Federal District experts on the EMPEROR-Reduced trial 'A new era in the treatment of patients with HF. From EMPA-REG OUTCOME to EMPEROR-Reduced trial'

50. Female and Male Phenotypes of Iron Deficiency in CHF. Additional analysis of the «The Prevalence of Iron Deficiency in Patients With Chronic Heart Failure in the Russian Federation (J-CHF-RF)» study

Catalog

Books, media, physical & digital resources